SGLT2 inhibitors in patients with heart failure with reduced ejection fraction
The administration of Sodium-glucose co-transporter-2 (SGLT2) inhibition was shown to reduce the composite endpoint of cardiovascular deaths or hospitalization for heart failure in patients...